MCID: SCH011
MIFTS: 32

Schizotypal Personality Disorder malady

Category: Mental diseases

Aliases & Classifications for Schizotypal Personality Disorder

About this section

Aliases & Descriptions for Schizotypal Personality Disorder:

Name: Schizotypal Personality Disorder 11 13 48 37 66
 
Schizotypal Personality 48

Classifications:



External Ids:

Disease Ontology11 DOID:10646
ICD1028 F21
ICD9CM30 301.22
SNOMED-CT60 231486008, 31027006
MeSH37 D012569
NCIt43 C92632

Summaries for Schizotypal Personality Disorder

About this section
Disease Ontology:11 A personality disorder that involves a need for social isolation, anxiety in social situations, odd behavior and thinking, and often unconventional beliefs.

MalaCards based summary: Schizotypal Personality Disorder, also known as schizotypal personality, is related to schizophrenia and avoidant personality disorder. An important gene associated with Schizotypal Personality Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways are Androgen receptor signaling pathway and Metabolism. Affiliated tissues include testes, brain and eye, and related mouse phenotype nervous system.

Wikipedia:69 Schizotypal personality disorder (STPD) or schizotypal disorder is a mental disorder characterized by... more...

Related Diseases for Schizotypal Personality Disorder

About this section

Graphical network of diseases related to Schizotypal Personality Disorder:



Diseases related to schizotypal personality disorder

Symptoms for Schizotypal Personality Disorder

About this section

Drugs & Therapeutics for Schizotypal Personality Disorder

About this section

Drugs for Schizotypal Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
GuanfacinePhase 4, Phase 25629110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine (INN)
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
2
SerotoninPhase 1, Phase 2351050-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
3
RisperidonePhase 1, Phase 2482106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
 
NCGC00015883-01
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
4
DopaminePhase 1, Phase 2367851-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
5Dopamine agonistsPhase 2611
6DIHYDREXIDINEPhase 24
7
OxytocinPhase 139050-56-6439302, 53477758
Synonyms:
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
(Arg8)-Vasopressin
(Arg8)-Vasotocin
1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
50-56-6
AC1L9735
Argipressin
Argpressin Acetate
BCBcMAP01_000094
Biotinyl-(Arg8)-Vasopressin
C00746
CHEBI:492195
CHEBI:7872
CHEMBL395429
CID439302
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
Cys-Tyr-Ile-Thr-Asn-Cys-Gly-Leu-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2
D00089
Disulfide bridge Cys1-Cys6
Gly-Leu-Pro-c
HS-2021
 
L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide
MolPort-003-938-941
NCGC00167132-01
O3251_SIGMA
O4375_SIGMA
OXT
OXYTOCIN
Ocytocin
Oxitocina
Oxytocic hormone
Oxytocin (JP15/USP/INN)
Oxytocin (TN)
Oxytocin 10 Usp Units In Dextrose 5%
Oxytocin 20 Usp Units In Dextrose 5%
Oxytocin 5 Usp Units In Dextrose 5%
Oxytocin Acetate
Oxytocin injection
Oxytocine
Oxytocinum
Pitocin
Pitocin (TN)
Syntocinon
Syntocinon (TN)
TI-001
alpha-Hypophamine
nchembio.184-comp2
8
sertraline29079617-96-268617
Synonyms:
(+)-Sertraline
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
(1S,4S)-Sertraline
(1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
(1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine
79559-97-0 (Hydrochloride)
79617-96-2
AB00514002
AB1004870
AC-15639
AC1L2A41
AC1Q3O5N
AC1Q3XJU
Apo-Sertraline
BIDD:GT0768
BIDD:PXR0193
BPBio1_001285
BRD-K82036761-003-02-1
BRN 5753709
BSPBio_001167
BSPBio_002698
C07246
C17H17Cl2N
CHEBI:9123
CHEMBL809
CID68617
CP 51974
Cp 51974
D02360
DB01104
DB08567
FT-0081122
HSDB 7037
KBio3_001918
 
KBioGR_001724
LS-94179
Lustral
MLS001195647
MLS002222308
MolPort-002-885-860
NCGC00092386-03
NCGC00092386-04
NCGC00092386-05
NCGC00092386-06
NCGC00092386-07
NCGC00092386-08
NCGC00092386-09
Prestwick3_001014
SMR000596516
SPBio_000385
SRE
Sertralina
Sertralina [Spanish]
Sertraline
Sertraline (INN)
Sertraline Hydrochloride
Sertraline [INN:BAN]
Sertraline [Zoloft]
Sertraline hydrochloride
Sertralinum
Sertralinum [Latin]
Spectrum2_000493
Spectrum3_001079
Spectrum4_001232
Sultamicillin Tosylate
UNII-QUC7NX6WMB
Zoloft
cis-(+)-Sertraline
sertraline
sertraline (Zoloft)
9
Pergolide1266104-22-147811
Synonyms:
(6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline
(8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline
(8beta)-8-[(methylthio)methyl]-6-propylergoline
66104-22-1
66104-23-2 (mesylate)
AC1L2IT3
AC1Q7DT2
BIDD:GT0177
BPBio1_000254
BPBio1_001211
BRD-K60770992-001-01-8
BRD-K60770992-066-05-2
BSPBio_000230
BSPBio_003156
Biomol-NT_000025
C07425
C19H26N2S
CHEBI:112494
CHEMBL531
CID47811
D08339
DB01186
DivK1c_000442
HMS2089C18
IDI1_000442
InChI=1/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s
KBio1_000442
KBio2_002127
KBio2_004695
KBio2_007263
KBio3_002656
KBioGR_001409
KBioSS_002127
 
LS-64479
LY-127,809
Lopac0_000984
MolPort-003-849-834
NCGC00017366-05
NCGC00142538-01
NCGC00142538-02
NCGC00142538-03
NINDS_000442
Pergolida
Pergolida [INN-Spanish]
Pergolide (INN)
Pergolide Mesylate
Pergolide Methanesulfonate
Pergolide [INN:BAN]
Pergolidum
Pergolidum [INN-Latin]
Permax
Permax (TN)
Prestwick0_000295
Prestwick1_000295
Prestwick2_000295
Prestwick3_000295
SPBio_002099
SPBio_002449
ST057534
Spectrum2_001970
Spectrum3_001588
Spectrum4_000835
Spectrum5_001649
Spectrum_001647
UNII-24MJ822NZ9
nchembio873-comp45
pergolide
10
Aripiprazole345129722-12-960795
Synonyms:
129722-12-9
24-29-3
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
AC-1554
AC1L1TXZ
AC1Q3T38
ALKS-9070
Abilify
Abilify (TN)
Abilify Discmelt
Abilitat
Aripiprazol
Aripiprazole
Aripiprazole (JAN/USAN/INN)
Aripiprazole [USAN]
Aripiprazolum
Aripirazole
Arpizol
Asprito|
BMS-337039
Bio-0004
Bristol-Myers Squibb brand of aripiprazole
C094645
C12564
C23H27Cl2N3O2
CHEBI:31236
CHEMBL1112
CID60795
CPD000466383
 
D01164
DB01238
Discmelt
FT-0082572
HMS2051I18
HMS2089M20
HMS2093F22
HSDB 7320
KS-1030
L001339
LS-142666
MLS000759517
MLS001165779
MLS001195621
MLS001424078
MolPort-002-885-808
MolPort-003-844-657
NCGC00159510-02
NCGC00159510-03
OPC 31
OPC-14597
OPC-31
Opc 14597
Otsuka brand of aripiprazole
Pripiprazole
S06-0010
SAM001246750
SMR000466383
STK625160
TL8000707
TL80090184
UNII-82VFR53I78
aripiprazol
aripiprazole
aripiprazolum
||OPC 14597

Interventional clinical trials:

(show all 18)
idNameStatusNCT IDPhase
1Pharmacology of Cognition in Schizotypal Personality DisorderRecruitingNCT00353379Phase 4
2Schizotypal Personality Disorder RisperidoneCompletedNCT02535156Phase 1, Phase 2
3Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality DisorderRecruitingNCT01466205Phase 2
4A D1 Agonist For Working MemoryRecruitingNCT02507206Phase 2
5CRT-Guanfacine for SPDRecruitingNCT02524899Phase 2
6Examining Dose-Related Effects of Oxytocin on Social Cognition Across PopulationsRecruitingNCT02149823Phase 1
7Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality DisorderCompletedNCT00158028
8A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological DysfunctionsCompletedNCT00155519
9Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) StudyCompletedNCT01269710
10Psychosis: Early Detection, Intervention and PreventionCompletedNCT01597141
11Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative SymptomsCompletedNCT00169988
12Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of PsychosisCompletedNCT01619319
13Pergolide for Cognitive Symptoms in Schizotypal Personality DisorderRecruitingNCT00252044
14Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult SampleRecruitingNCT02800681
15Extended Specialized Assertive Intervention for First Episode PsychosisActive, not recruitingNCT00914238
16Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode PsychosisActive, not recruitingNCT00157313
17Health Promotion on Young Adults With High Risk Disability for Mental HealthActive, not recruitingNCT01740167
18Aripiprazole Treatment of the ProdromeTerminatedNCT00169949

Search NIH Clinical Center for Schizotypal Personality Disorder


Cochrane evidence based reviews: schizotypal personality disorder

Genetic Tests for Schizotypal Personality Disorder

About this section

Anatomical Context for Schizotypal Personality Disorder

About this section

MalaCards organs/tissues related to Schizotypal Personality Disorder:

34
Testes, Brain, Eye, Caudate nucleus, Temporal lobe, Pituitary, Breast

Animal Models for Schizotypal Personality Disorder or affiliated genes

About this section

MGI Mouse Phenotypes related to Schizotypal Personality Disorder:

39
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00036317.9CACNA1C, COMT, EP300, FLNA, PSAT1

Publications for Schizotypal Personality Disorder

About this section

Articles related to Schizotypal Personality Disorder:

(show top 50)    (show all 185)
idTitleAuthorsYear
1
Schizotypal personality disorder: a current review. (24828284)
2014
2
Schizotypal personality disorder. (22928856)
2013
3
Neuroimaging findings in schizotypal personality disorder: a systematic review. (23220094)
2013
4
Semantic processing impairment in individuals with schizotypal personality disorder features: a preliminary event-related potential study. (22960083)
2013
5
CACNA1C as a risk factor for schizotypal personality disorder and schizotypy in healthy individuals. (22985546)
2013
6
Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. (24200416)
2013
7
Prodromal and autistic symptoms in schizotypal personality disorder and 22q11.2 deletion syndrome. (22686870)
2013
8
Some suggestions for the DSM-5 schizotypal personality disorder construct. (21741634)
2012
9
Dorso- and ventro-lateral prefrontal volume and spatial working memory in schizotypal personality disorder. (21115066)
2011
10
Deficient visual sensitivity in schizotypal personality disorder. (20541911)
2011
11
Prodromal symptoms in adolescents with 22q11.2 deletion syndrome and schizotypal personality disorder. (21507614)
2011
12
Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. (20130535)
2010
13
Smaller superior temporal gyrus volume specificity in schizotypal personality disorder. (19473820)
2009
14
Clozapine in treatment-refractory obsessive-compulsive disorder with comorbid schizotypal personality disorder. (19398826)
2008
15
Elevated social Internet use and schizotypal personality disorder in adolescents. (17532188)
2007
16
Anorexia nervosa with chronic episodes for more than 30 years in a patient with a comorbid schizotypal personality disorder. (17610670)
2007
17
Sex differences in digit ratio (2D:4D) are disrupted in adolescents with schizotypal personality disorder: altered prenatal gonadal hormone levels as a risk factor. (16806835)
2006
18
Catechol-O-methyltransferase Val158Met genotype variation is associated with prefrontal-dependent task performance in schizotypal personality disorder patients and comparison groups. (16691129)
2006
19
Clinical, cognitive, and social characteristics of a sample of neuroleptic-naive persons with schizotypal personality disorder. (15985362)
2005
20
A comparative profile analysis of neuropsychological function in men and women with schizotypal personality disorder. (15694753)
2005
21
The five-factor model in schizotypal personality disorder. (16168625)
2005
22
Neuropsychological performance in schizotypal personality disorder: importance of working memory. (16199836)
2005
23
Processing sentence context in women with schizotypal personality disorder: an ERP study. (15102121)
2004
24
A MRI study of fusiform gyrus in schizotypal personality disorder. (14511799)
2003
25
Deficient attentional modulation of the startle response in patients with schizotypal personality disorder. (12944337)
2003
26
Generalized cognitive impairment in male adolescents with schizotypal personality disorder. (12497611)
2003
27
Risperidone in the treatment of schizotypal personality disorder. (12823075)
2003
28
MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder. (12091198)
2002
29
Differential metabolic rates in prefrontal and temporal Brodmann areas in schizophrenia and schizotypal personality disorder. (11853988)
2002
30
Prefrontal structural and functional deficits in schizotypal personality disorder. (12645681)
2002
31
Semantic dysfunction in women with schizotypal personality disorder. (12359685)
2002
32
Abnormalities of auditory event-related potentials in students with schizotypal personality disorder. (11555339)
2001
33
Executive functions in adolescents with schizotypal personality disorder. (10742650)
2000
34
Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. (10618013)
2000
35
Visuospatial working memory in schizotypal personality disorder patients. (10728721)
2000
36
Large CSF volume not attributable to ventricular volume in schizotypal personality disorder. (10618012)
2000
37
Schizotypal personality disorder and MRI abnormalities of temporal lobe gray matter. (10356620)
1999
38
Electrophysiological correlates of language processing in schizotypal personality disorder. (10401451)
1999
39
MRI study of cavum septi pellucidi in schizophrenia, affective disorder, and schizotypal personality disorder. (9545997)
1998
40
Abnormal orienting in schizotypal personality disorder. (9050114)
1997
41
Neuropsychological dysfunction in schizotypal personality disorder: a profile analysis. (9046985)
1997
42
Topographic abnormalities of P3 in schizotypal personality disorder. (8830949)
1996
43
The relationship of information-processing deficits and clinical symptoms in schizotypal personality disorder. (8896771)
1996
44
Impaired eye tracking in undergraduates with schizotypal personality disorder. (8417560)
1993
45
Self-amputation of the breasts by a male with schizotypal personality disorder. (1572617)
1992
46
'Schizoid' personality in childhood and adult life. II: Adult adjustment and the continuity with schizotypal personality disorder. (1756337)
1991
47
Formal thought disorder in childhood onset schizophrenia and schizotypal personality disorder. (2289947)
1990
48
Eye tracking impairment in clinically identified patients with schizotypal personality disorder. (2343917)
1990
49
Eye tracking, schizophrenic symptoms, and schizotypal personality disorder. (2792157)
1989
50
Coexistent obsessive-compulsive disorder and schizotypal personality disorder: a poor prognostic indicator. (3954553)
1986

Variations for Schizotypal Personality Disorder

About this section

Expression for genes affiliated with Schizotypal Personality Disorder

About this section
Search GEO for disease gene expression data for Schizotypal Personality Disorder.

Pathways for genes affiliated with Schizotypal Personality Disorder

About this section

Pathways related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.1EP300, FLNA
2
Show member pathways
7.6CACNA1C, COMT, EP300, PSAT1, SULT4A1

GO Terms for genes affiliated with Schizotypal Personality Disorder

About this section

Biological processes related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein stabilizationGO:00508219.1EP300, FLNA

Molecular functions related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1SMAD bindingGO:00463329.1EP300, FLNA

Sources for Schizotypal Personality Disorder

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet